Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:category |
antiretroviral therapy
|
| gptkbp:combines |
gptkb:NNRTIs
gptkb:NRTIs PIs |
| gptkbp:concerns |
HIV integrase mutations
|
| gptkbp:contraindication |
hypersensitivity to components
|
| gptkbp:discoveredIn |
2000s
|
| gptkbp:hasApprovedDrug |
gptkb:raltegravir
|
| https://www.w3.org/2000/01/rdf-schema#label |
INSTIs
|
| gptkbp:includesDrug |
gptkb:cabotegravir
gptkb:dolutegravir gptkb:elvitegravir gptkb:raltegravir bictegravir |
| gptkbp:mechanismOfAction |
inhibit HIV integrase enzyme
|
| gptkbp:pregnancyCategory |
varies by drug
|
| gptkbp:routeOfAdministration |
oral
injectable |
| gptkbp:sideEffect |
nausea
diarrhea headache insomnia |
| gptkbp:standsFor |
gptkb:Integrase_Strand_Transfer_Inhibitors
|
| gptkbp:usedFor |
HIV treatment
|
| gptkbp:bfsParent |
gptkb:HIV/AIDS
|
| gptkbp:bfsLayer |
4
|